glp-1 when to take medications safe continue before surgery in patients with diabetes and obesity How Long Does It Take

With activist investors bemoaning returns on R&D and M&A investment and the loss of about $17bn in revenues looming from exclusivity expiries in 20252030, the company has been culling its pipeline and looking externally for assets

Our review of the clinical trial pipeline reveals 39 new GLP-1 drugs in development from 34 companies, with only seven among the top 20 pharmaceutical companies

In 2025, the company delivered a strong +19.93% YoY revenue growth, driven by its immunology leadership: Dupixent ($18.48B) continues to be the primary growth engine with expanding indications and global uptake, while Lantus ($2.03B) and Toujeo ($1.58B) remain important contributors in diabetes, albeit facing competitive and pricing pressures reflecting a clear transition toward specialty medicines

This helps people with type 2 diabetes maintain better glycemic control and prevents spikes and crashes that can occur with rapid digestion